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Optimal, Two Stage, Adaptive Enrichment Designs for
Randomized Trials, using Sparse Linear Programming
Michael Rosenblum∗, Xingyuan Fang†, and Han Liu†
December 15, 2014
Abstract
Adaptive enrichment designs involve preplanned rules for modifying enrollment
criteria based on accruing data in a randomized trial. Such designs have been pro-
posed, for example, when the population of interest consists of biomarker positive and
biomarker negative individuals. The goal is to learn which populations benefit from
an experimental treatment. Two critical components of adaptive enrichment designs
are the decision rule for modifying enrollment, and the multiple testing procedure. We
provide the first general method for simultaneously optimizing both of these compo-
nents for two stage, adaptive enrichment designs. We minimize expected sample size
under constraints on power and the familywise Type I error rate. It is computationally
infeasible to directly solve this optimization problem since it is not convex. The key
to our approach is a novel representation of a discretized version of this optimization
problem as a sparse linear program. We apply advanced optimization methods to solve
this problem to high accuracy, revealing new, approximately optimal designs.
1 Introduction
Consider the problem of planning a randomized trial of a new treatment versus control, when
the population of interest is partitioned into two subpopulations. The subpopulations could
be defined in terms of a biomarker or risk score measured at baseline. Our goal is to test the
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†Department of Operations Research and Financial Engineering, Princeton University
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null hypotheses of no average treatment benefit for each subpopulation and for the combined
population. Standard randomized trial designs may have low power to detect a treatment
effect if the treatment only benefits one subpopulation. Adaptive enrichment designs have
been proposed for this problem, e.g., Follmann (1997), Russek-Cohen and Simon (1997),
Jennison and Turnbull (2007), Wang et al. (2007), Wang et al. (2009), Brannath et al.
(2009a), Rosenblum and van der Laan (2011), Jenkins et al. (2011a), Friede et al. (2012),
Boessen et al. (2013a), Stallard et al. (2014).
An adaptive enrichment design consists of a decision rule for potentially modifying enroll-
ment at an interim analysis, and a multiple testing procedure. The decision rule is allowed
to be an arbitrary, prespecified function from the stage 1 data to a finite set of possible
enrollment decisions for stage 2. The multiple testing procedure can be an arbitrary, pre-
specified function from the stage 1 and 2 data to the set of null hypotheses that are rejected.
The class of possible designs is therefore quite large. Our goal is to construct new adaptive
enrichment designs that minimize expected sample size under constraints on power and Type
I error, over this class of possible designs. This is a nonconvex optimization problem that is
computationally infeasible to solve directly.
Our approach is to approximate the original optimization problem by a large, sparse linear
program. This idea was used in the context of standard (non-adaptive) designs by Rosenblum
et al. (2014), where the only feature optimized was the multiple testing procedure. We tackle
the substantially more challenging problem of simultaneously optimizing the decision rule
and multiple testing procedure in two-stage, adaptive enrichment designs. The difficulty of
the latter problem is twofold: it is both harder to construct a representation as a sparse,
linear program, and the resulting linear program is harder to solve computationally. Another
difference between the work here and Rosenblum et al. (2014) is that we consider not only
power, but also expected sample size. In practice, both of these are important considerations
in trial planning.
We prove that our designs control the familywise Type I error rate in the strong sense
defined by Hochberg and Tamhane (1987, pg. 3). Control of the familywise Type I error rate
is generally required by regulatory agencies such as the U.S. Food and Drug Administration
for confirmatory randomized trials (FDA, 2010).
As in all of the above related work, we require the subpopulations to be defined before the
trial starts. Such a definition could be based on prior trial data and scientific understanding
of the disease being treated. Designs exist that try to solve the more challenging problem
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of defining a subpopulation based on accruing data and then testing for a treatment effect
in that subpopulation, e.g., Freidlin and Simon (2005); Lai et al. (2014). Optimizing trial
designs in this context is an area of future work.
Hampson and Jennison (2014) consider the related problem of optimizing a two-stage
adaptive design to determine the optimal treatment among k possible treatments, for a
single population. Their general approach of converting the problem to a Bayes decision
problem does not work in our setting, since this approach requires that the optimal solution
at the global null hypothesis also controls familywise Type I error at all other alternatives.
We show in Section 7 that this does not generally hold for our problem.
We focus on designs where the only allowed adaptation is to modify enrollment for stage
2. Other types of adaptive designs involve modifying randomization probabilities (called
covariate-adaptive or response-adaptive designs), or modifying the treatment for each indi-
vidual in response to his/her outcomes over time (called dynamic treatment regimes). In
contrast to these types of adaptation, each participant in our designs is randomized with
probability 1/2 to treatment or control, and once he/she is randomized there is no change
to the treatment received. The only design feature that may be changed is the stage 2
enrollment criteria.
2 Problem Definition
2.1 Null Hypotheses
We assume the population is partitioned into two subpopulations, defined in terms of vari-
ables measured before randomization. Let ps denote the proportion of the population in
subpopulation s ∈ {1, 2}, which we assume are known; p1 + p2 = 1. Each enrolled partic-
ipant is assigned to treatment (a = 1) or control (a = 0) with probability 1/2. Below, for
clarity, we focus on normally distributed outcomes with known variances. However, we give
asymptotic extensions of our results for a wide variety of outcome distributions in Section A
of the Supplementary Materials.
For each subpopulation s ∈ {1, 2} and stage k ∈ {1, 2}, we assume exactly half the
participants are assigned to each study arm a ∈ {0, 1}. This can be approximately achieved
in practice by using block randomization stratified by subpopulation. For each participant i
from subpopulation s ∈ {1, 2} enrolled in stage k ∈ {1, 2}, let (A(k)s,i , Y (k)s,i ) denote his/her arm
3
Hosted by The Berkeley Electronic Press
assignment A
(k)
s,i ∈ {0, 1} and outcome Y (k)s,i ∈ R, respectively. Throughout, the subpopulation
indicator s is in the subscript, and the stage number k is in the superscript. We assume that
conditioned on A
(k)
s,i = a, the outcome Y
(k)
s,i ∼ N(µsa, σ2sa) and is independent of all other
participant data. Let σ2 = (σ210, σ
2
11, σ
2
20, σ
2
21), which we assume are known. Let X
(k) denote
all the data from stage k, and let X = X(1) ∪X(2) denote the cumulative data at the end of
stage 2. Let X (k) and X denote the sample spaces corresponding to X(k) and X, respectively.
Denote the population average treatment effect for each subpopulation s ∈ {1, 2} by ∆s =
µs1−µs0, and for the combined population by ∆C = p1∆1 +p2∆2. Let ∆ = (∆1,∆2). Define
H01, H02, H0C , to be the null hypotheses of no average treatment benefit in subpopulation
1, subpopulation 2, and the combined population, respectively, i.e.,
H01 : ∆1 ≤ 0; H02 : ∆2 ≤ 0; H0C : ∆C ≤ 0.
Let H = {H01, H02, H0C}, and let S denote the power set of H. For any ∆ ∈ R2, define
HTRUE(∆) to be the set of true null hypotheses at ∆. For each s ∈ {1, 2}, this set contains
H0s if ∆s ≤ 0; it contains H0C if p1∆1 + p2∆2 ≤ 0.
2.2 Two-Stage Adaptive Enrichment Designs
In stage 1, n
(1)
s participants are enrolled from each subpopulation s. At the interim analysis
following stage 1, a decision rule D determines the number of participants to enroll from
each subpopulation in stage 2. This decision is based on the data from stage 1, and there
are K <∞ possible decisions denoted by D = {1, . . . , K}. At the end of stage 2, a multiple
testing procedure M determines which subset (if any) of the null hypotheses to reject, based
on the data from stages 1 and 2. A two stage adaptive enrichment design is defined by the
following quantities, which must be specified before the trial starts:
i. The stage 1 sample sizes n
(1)
1 , n
(1)
2 for subpopulations 1 and 2, respectively.
ii. The number K of possible stage 2 decisions, and for each decision d ∈ D = {1, . . . , K}
the stage 2 sample sizes n
(2),d
1 , n
(2),d
2 for subpopulations 1 and 2, respectively.
iii. A decision rule D mapping the stage 1 data X(1) to an enrollment decision in D.
iv. A multiple testing procedure M mapping the stage 1 and 2 data X to a set of hypothe-
ses H ⊆ H to reject.
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Define an adaptive design template to be the quantities defined in (i)-(ii), i.e., the set
of possible decisions and corresponding sample sizes n = (D, n(1)1 , n(1)2 , {n(2),d1 , n(2),d2 }d∈D). A
general adaptive design template is displayed in Figure 1a. A specific example of an adaptive
design template is given in Figure 1b for the case of p1 = 1/2. In this example, for a given
n > 0, the stage 1 sample sizes satisfy n
(1)
1 = n
(1)
2 = n/4. There are four choices for stage
2 enrollment: D = 1: stop the trial, i.e., n
(2),1
1 = n
(2),1
2 = 0; D = 2: enroll exactly as in
stage 1, i.e., n
(2),2
1 = n
(2),2
2 = n/4; D = 3: only enroll from subpopulation 1, i.e., n
(2),3
1 =
3n/4, n
(2),3
2 = 0; D = 4: only enroll from subpopulation 2, i.e., n
(2),4
1 = 0, n
(2),4
2 = 3n/4.
For a given adaptive design template n, we aim to simultaneously optimize the decision
rule D and multiple testing procedure M , in the sense defined in Section 2.3. The only
constraints on D and M are that they are measurable functions as defined in Appendix B of
the Supplementary Materials. Let E∗ denote the class of all measurable functions from the
sample space X (1) to D, and let M∗ denote the class of all measurable functions from the
sample space and decision X × D to the power set S of null hypotheses. For given values
of (n,σ, D,M), let P∆ denote the corresponding distribution of X and and let E∆ denote
expectation with respect to this distribution.
2.3 General Optimization Problem
The quantity to be minimized, called the objective function, is defined in terms of a loss
function L and a distribution Λ on the alternatives ∆. The loss function and distribution
are set by the user to determine the quantity of interest to be optimized, e.g., these can be
chosen to represent expected sample size and/or power as described below. We allow the loss
function L to be any bounded, integrable function of the treatment effect ∆, the enrollment
decision D, and the set of hypotheses rejected M . For a given loss function L, the risk at
treatment effect vector ∆ ∈ R2 is defined as RL(∆) = E∆L[M{X,D(X(1))}, D(X(1)),∆].
The objective function is the Bayes risk
∫
RL(∆)dΛ(∆). Below, for clarity of notation, we
write D for D(X(1)) and M for M{X,D(X(1))}.
The above definition of the objective function allows us to select different quantities of
interest (or weighted combinations of these quantities) to optimize, e.g., power, expected
sample size, or expected number assigned to an ineffective treatment. For example, the loss
function could be set equal to the total sample size LSS = n
(1)
1 + n
(1)
2 + n
(2),D
1 + n
(2),D
2 ; the
corresponding risk at ∆ ∈ R2 equals the expected sample size of the trial when the treatment
5
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Figure 1: (a) Adaptive enrichment design template; (b) Example of adaptive enrichment
design.
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effect is ∆. Alternatively, we could encode power to reject different null hypotheses using
the following loss functions:
For each s ∈ {1, 2}, L(s) = 1[H0s /∈M ; ∆s ≥ ∆min];
L(C) = 1[H0C /∈M,∆1 ≥ ∆min,∆2 ≥ ∆min],
where ∆min represents the minimum, clinically meaningful treatment effect, which is user-
specified. The reason we put the constraint ∆s ≥ ∆min in the loss function L(s) is that
we only want to penalize for failing to reject H0s when in truth the treatment effect for
subpopulation s is above the clinically meaningful level. For each subpopulation s ∈ {1, 2},
if the treatment effect ∆s equals or exceeds the minimum level ∆
min, then the risk RL(s)(∆)
equals one minus the power to reject H0s. Similarly, if both treatment effects ∆1,∆2 equal
or exceed the minimum level, the risk RL(C)(∆) equals one minus the power to reject H0C .
In either case, minimizing risk corresponds to maximizing power.
We aim to minimize the Bayes risk, i.e., the risk integrated with respect to a distribution
Λ on the alternatives ∆. For example, we could let Λ denote a weighted sum of the four
point masses in the set Q = {(0, 0), (∆min, 0), (0,∆min), (∆min,∆min)}, which correspond to
no treatment effect, only subpopulation 1 benefiting at the minimum level, only subpopula-
tion 2 benefiting at the minimum level, and both subpopulations benefiting at the minimum
level, respectively. Let Λpm denote this distribution with weight 1/4 on each point mass.
Let Λmix denote a mixture of four normal distributions, with one centered at each of the
aforementioned point masses, and each having variance σ2Λ. Then the Bayes risk correspond-
ing to the pair (L,Λ) = (LSS,Λpm) is the expected sample size under ∆, averaged over
the four scenarios ∆ ∈ Q. As another example, the Bayes risk corresponding to the pair
(L,Λ) = (a1L
(1) + a2L
(2),Λmix) for positive constants a1, a2 is the weighted sum of 1 minus
the power to reject each H0s when the corresponding treatment effect exceeds the minimum
level, integrated over the distribution Λmix(∆).
Our optimization problem has two types of constraints. The first are familywise Type I
error constraints, and the second are additional constraints involving J triples (Lj,Λj, βj) of
loss function Lj, distribution Λj(∆), and threshold βj ∈ R defined below.
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Constrained Bayes Optimization Problem: For given n, α > 0, σ2,
{(Lj,Λj, βj) : j = 0, . . . , J}, find the adaptive enrichment design (D,M) ∈
(E∗ ×M∗) minimizing∫
E∆
(
L0[M{X,D(X(1))}, D(X(1)),∆]
)
dΛ0(∆), (1)
under the familywise Type I error constraints: for any ∆ ∈ R2,
P∆ {M rejects any null hypotheses in HTRUE(∆)} ≤ α, (2)
and additional constraints: for each j ∈ {1, . . . , J}:∫
E∆
(
Lj[M{X,D(X(1))}, D(X(1)),∆]
)
dΛj(∆) ≤ βj. (3)
First, consider the case where J = 0, i.e., there are no additional constraints (3). Then
the constrained Bayes optimization problem is to minimize the Bayes risk subject to strong
control on the familywise Type I error rate at level α. For example, one can optimize power
in the sense described above by setting (L,Λ) = (a1L
(1) + a2L
(2),Λmix).
2.4 Example of Optimization Problem
The additional constraints (3) allow the user to define a broader set of problems, such as
optimizing expected sample size subject to power and Type I error constraints. For example,
consider the problem of minimizing expected sample size averaged over the four point masses
in Q, under the Type I error constraints (2) and the following power constraints for given
Type II error β > 0:
P1. At (∆1,∆2) = (∆
min, 0), the power to reject H01 is at least 1− β.
P2. At (∆1,∆2) = (0,∆
min), the power to reject H02 is at least 1− β.
P3. At (∆1,∆2) = (∆
min,∆min), the power to reject H0C is at least 1− β.
This problem can be represented by setting (L,Λ) = (LSS,Λpm) and J = 3 additional
constraints of the form (Lj,Λj, βj) equal to
(L(1), 1(∆min, 0), β); (L(2), 1(0,∆min), β); (L(C), 1(∆min,∆min), β),
where 1(x, y) denotes a point mass at ∆ = (x, y). We solve this problem in Section 5.
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3 Reducing Problem Complexity through Minimal Suf-
ficient Statistics
We show that it suffices to consider decision rules D and multiple testing procedures M
that depend only on minimal sufficient statistics. This dramatically reduces the problem
complexity from having to search over arbitrarily complex functions of the data X, to the
easier (but still very challenging) problem of searching over functions of the 2-dimensional
sufficient statistics at each stage. Let N
(k)
s denote the number enrolled from subpopulation
s ∈ {1, 2} during stage k ∈ {1, 2}. The stage 1 sample sizes are set in advance, while
the stage 2 sample sizes are functions of the stage 1 data; specifically, N
(1)
s = n
(1)
s and
N
(2)
s = n
(2),D(X(1))
s for each s ∈ {1, 2}.
For each subpopulation s ∈ {1, 2} and stage k ∈ {1, 2}, define the corresponding z-
statistic as
Z(k)s =

∑N(k)s
i=1 Y
(k)
s,i A
(k)
s,i∑N(k)s
i=1 A
(k)
s,i
−
∑N(k)s
i=1 Y
(k)
s,i (1− A(k)s,i )∑N(k)s
i=1 (1− A(k)s,i )

{
σ2s1 + σ
2
s0
N
(k)
s /2
}−1/2
, (4)
where the quantity inside curly braces on the right is the variance of the difference between
sample means on the left. Let Z(k) = (Z
(k)
1 , Z
(k)
2 ). Define the final (cumulative) z-statistic
based on all stage 1 and 2 data for subpopulation s by
Z(F )s =

∑2
k=1
∑N(k)s
i=1 Y
(k)
s,i A
(k)
s,i∑2
k=1
∑N(k)s
i=1 A
(k)
s,i
−
∑2
k=1
∑N(k)s
i=1 Y
(k)
s,i (1− A(k)s,i )∑2
k=1
∑N(k)s
i=1 (1− A(k)s,i )

{
σ2s1 + σ
2
s0
(N
(1)
s +N
(2)
s )/2
}−1/2
.
(5)
Let Z(F ) = (Z
(F )
1 , Z
(F )
2 ). The distribution of Z = (Z
(1),Z(F )) is characterized as follows:
a. Z(1) is bivariate normal with mean vector
(
∆1
{
n
(1)
1
2(σ211+σ210)
}1/2
,∆2
{
n
(1)
2
2(σ221+σ220)
}1/2)
and covariance matrix I2, i.e., the 2× 2 identity matrix.
b. Z(2), which uses only stage 2 data, is conditionally independent of Z(1) given the decision
D(Z(1), U1). The conditional distribution of Z
(2) given D(Z(1), U1) = d is bivariate
normal with mean vector
(
∆1
{
n
(2),d
1
2(σ211+σ210)
}1/2
,∆2
{
n
(2),d
2
2(σ221+σ220)
}1/2)
and covariance
matrix I2.
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c. For each subpopulation s ∈ {1, 2}, for D = D(Z(1), U1), we have the following relation-
ship between the final (cumulative) z-statistic and the stagewise z-statistics:
Z(F )s =
{
n
(1)
s
n
(1)
s + n
(2),D
s
}1/2
Z(1)s +
{
n
(2),D
s
n
(1)
s + n
(2),D
s
}1/2
Z(2)s . (6)
We show that it suffices to consider decision rules D that depend on the data only
through Z(1), and multiple testing procedures M that depend on the data only through Z(F )
and the decision D. We consider randomized decision rules and multiple testing procedures,
i.e., we allow D and M to additionally take as input U1 and U2, respectively, which are
independent, uniform random variables. For conciseness, we refer to “randomized decision
rules” as “decision rules”, and refer to “randomized multiple testing procedures” as “multiple
testing procedures.”
Let E denote the class of all measurable functions D from R2 × [0, 1] (representing all
possible values of Z(1), U1) to the set of stage 2 enrollment decisions D. Let M denote the
class of all measurable functions from R2 × D × [0, 1] (representing all possible values of
Z(F ), D(Z(1), U1), U2) to S (indicating the subset of null hypotheses rejected). For concise-
ness, we let D = D(Z(1), U1) and M = M{Z(F ), D(Z(1), U1), U2}. Define the class of adaptive
enrichment designs A = {(D,M) : D ∈ E ,M ∈ M}. We prove the following theorem in
Section J of the Supplementary Materials:
Theorem 3.1. If the constrained Bayes optimization problem in Section 2.3 is feasible, then
there exists an optimal solution (D,M) ∈ (E ×M), i.e., for which D depends on the data
only through Z(1), and M depends on the data only through Z(F ) and the decision D(Z(1), U1).
4 Discretization of Constrained Bayes Optimization Prob-
lem and Transformation into Sparse Linear Program
4.1 Discretization of Constrained Bayes Optimization Problem
Even after simplifying the constrained Bayes optimization problem by using only minimal
sufficient statistics as in the previous section, the problem is still extremely difficult or
impossible to solve directly. This is because the optimization problem is nonconvex, involves
infinitely many familywise Type I error constraints (2), and optimizes over the very large
10
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class of decision rules E and multiple testing proceduresM. We propose a novel approach to
solve this problem, involving three steps. We first discretize the decision rule and multiple
testing procedure, and restrict to a finite subset of familywise Type I error constraints. The
resulting problem is still nonconvex, and so is extremely difficult to solve. Step two involves
reparametrizing this problem so that it can be represented as a sparse, linear program, a
class of problems that is much easier to solve than nonconvex problems. The third step is
to apply advanced optimization methods to solve the sparse, linear program.
The first of the above steps is to discretize the constrained Bayes optimization problem.
The decision rule D is discretized by partitioning R2 into a finite set of rectangles as described
below. The intuition for what follows is that we restrict to the subclass of adaptive designs
(D,M) ∈ (E ×M) such that the following hold: D makes the same decision when the first
stage statistics Z(1) are anywhere within a small rectangle r ⊆ R2; M rejects the same set of
null hypotheses when the first stage statistics Z(1) are in a rectangle r ⊆ R2, the enrollment
decision is d ∈ D, and the final statistics Z(F ) are in a rectangle r′. For a fine enough
partition of rectangles, we expect the solution to the corresponding discretized optimization
problem to be close to that of the original problem.
We consider partitions of R2 into rectangles. One way to construct such a partition is
to start with a box B = [−b, b] × [−b, b], for a given integer b > 0. Let τ = (τ1, τ2) be
such that b/τs is an integer for each s ∈ {1, 2}. For each k, k′ ∈ Z, define the rectangle
Rk,k′ = [kτ1, (k + 1)τ1) × [k′τ2, (k′ + 1)τ2). Let RB denote the set of such rectangles in the
bounded region B, i.e., {Rk,k′ : k, k′ ∈ Z, Rk,k′ ⊂ B}. Define the following partition of R2:
R = RB ∪ {R2 \ B}. Though R2 \ B is not a rectangle, we still refer to R as a partition of
rectangles, with a slight abuse of notation.
Let Rdec denote a partition of R2 into rectangles. We restrict to the subclass of decision
rules D with the following property: for any rectangle r ∈ Rdec and u ∈ [0, 1],
D(z(1), u) = D(z(1)
′
, u) whenever z(1) and z(1)
′
are both in r. (7)
That is, the decision rule only depends on the data through the rectangle that the first stage
z-statistics are in.
For each d ∈ D, let Rmtp,d denote a partition of R2 into rectangles. Intuitively, we
will restrict to multiple testing procedures M that only depend on the data through the
enrollment decision D and the rectangles that the first stage and cumulative statistics are
in, respectively. Let z = (z(1), z(F )) and z′ = (z(1)
′
, z(F )
′
), for any z(1), z(F ), z(1)
′
, z(F )
′ ∈ R2.
11
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We restrict to the subclass of multiple testing procedures M such that for any r ∈ Rdec,
d ∈ D, r′ ∈ Rmtp,d, and u1, u2 ∈ [0, 1], we have M(z, d, u2) = M(z′, d, u2) whenever all of
the following hold: z(1) and z(1)
′
are both in r, D(z(1), u1) = D(z
(1)′ , u1), and z
C and zC
′
are
both in r′.
For each r ∈ Rdec and d ∈ D, define xrd to be the probability that decision d is made
conditioned on Z(1) ∈ r, i.e.,
xrd = P
{
D(Z(1), U1) = d|Z(1) ∈ r
}
. (8)
For each r ∈ Rdec, d ∈ D, r′ ∈ Rmtp,d, s ∈ S, define yrdr′s to be the probability that precisely
the subset s is rejected conditioned on Z(1) ∈ r, D(Z(1), U1) = d,Z(F ) ∈ r′, i.e.,
yrdr′s = P
{
M(Z, d, U2) = s|Z(1) ∈ r,D(Z(1), U1) = d,Z(F ) ∈ r′
}
. (9)
The values of all variables xrd and yrdr′s are specified by the study designer before the trial,
and our goal is to optimize the corresponding Bayes risk under familywise Type I error
constraints and the additional constraints (3).
The probability of rejecting precisely the subset s ∈ S at a given vector of population
parameters ∆ = (∆1,∆2) ∈ R2 is
P∆
{
M(Z, D(Z(1), U1), U2) = s
}
(10)
=
∑
r,d,r′
P∆
{
Z(1) ∈ r,D(Z(1), U1) = d,Z(F ) ∈ r′,M(Z, d, U2) = s
}
=
∑
r,d,r′
[
P∆
{
M(Z, d, U2) = s|Z(F ) ∈ r′,Z(1) ∈ r,D(Z(1), U1) = d
} ×
P∆
{
Z(F ) ∈ r′|Z(1) ∈ r,D(Z(1), U1) = d
}
P∆
{
D(Z(1), U1) = d|Z(1) ∈ r
}
P∆
{
Z(1) ∈ r}]
=
∑
r,d,r′
xrdyrdr′sp(∆, r, d, r
′), (11)
where (11) follows from (8) and (9), and where we define
p(∆, r, d, r′) = P∆
{
Z(F ) ∈ r′|Z(1) ∈ r,D(Z(1), U1) = d
}
P∆
{
Z(1) ∈ r} . (12)
The value of p(∆, r, d, r′) does not depend on D, which follows from (7). This value can be
computed to high precision using the multivariate normal distribution function and (a)-(c)
from Section 2.2, as described in Section F of the Supplementary Material.
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We can express the objective function (1) of the constrained Bayes optimization problem
in terms of the variables xrdyrdr′s, since the expectation inside the integral in (1) satisfies
E∆
{
L(M(Z, D(Z(1), U1), U2); ∆1,∆2)
}
=
∑
s∈S
L(s; ∆1,∆2)P (M(Z, D(Z
(1), U1), U2) = s)
=
∑
s∈S
L(s; ∆1,∆2)
∑
r,d,r′
xrdyrdr′sp(∆, r, d, r
′)
=
∑
s∈S
∑
r,d,r′
xrdyrdr′s {L(s; ∆1,∆2)p(∆, r, d, r′)} .
where the second line follows from the equality of (10) and (11). The familywise Type I
error constraints and additional constraints (3) can similarly be expressed as a function of
xrdyrdr′s, as shown in Section G of the Supplementary Materials.
Let G ⊂ R2 denote a discretization of the boundaries of the null spaces of the hypotheses
of interest; an example is given in Section 7. The discretized version of the Constrained
Bayes Optimization Problem above is as follows:
Discretized Problem:
min
∑
r,d,r′,s
xrdyrdr′s
∫
L0(s; ∆)p(∆, r, d, r
′)dΛ0(∆) (13)
under the following constraints:
for each ∆ ∈ G,
∑
r,d,r′
∑
s∈S:s∩HTRUE(∆)6=∅
xrdyrdr′sp(∆, r, d, r
′) ≤ α; (14)
for each j ∈ {1, . . . , J},
∑
r,d,r′,s
xrdyrdr′s
∫
Lj(s; ∆)p(∆, r, d, r
′)dΛj(∆) ≤ βj; (15)
for each r ∈ Rdec,
∑
d∈D
xrd = 1; (16)
for each r ∈ Rdec, d ∈ D, r′ ∈ Rmtp,d,
∑
s∈S
yrdr′s = 1; (17)
for each r ∈ Rdec, d ∈ D, r′ ∈ Rmtp,d, s ∈ S : xrd ≥ 0, yrdr′s ≥ 0. (18)
The sum
∑
r,d,r′,s, which appers in (13) and (15), is taken over r ∈ Rdec, d ∈ D, r′ ∈
Rmtp,d, s ∈ S. The objective function (13) represents (1). The constraints (14) and (15)
represent the familywise Type I error constraints (2) and additional constraints (3), respec-
tively. The remaining constraints encode properties of xrd and yrdr′s that follow from their
definitions (8)-(9) as conditional probabilities. Specifically, the constraints (16) and (17)
follow from the law of total probability; the constraints (18) encode that each variable must
be nonnegative since it represents a probability.
13
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4.2 Transformation of (Nonconvex) Discretized Problem into Sparse
Linear Program
The discretized problem from Section 4 is not linear (and not convex) in the variables
{xrd, yrdr′s}. Therefore, this problem is generally computationally intractable to solve, since
only ad hoc methods exist for solving nonconvex optimization problems and even if a local
minimum is found there is no general way to determine if it is the global minimum. We
transform this problem into a sparse, linear program by defining the new variables:
vrdr′s = xrdyrdr′s, for all r ∈ Rdec, d ∈ D, r′ ∈ Rmtp,d, s ∈ S. (19)
The objective function (13) and familywise Type I error constraints (14) are linear functions
of vrdr′s. We prove in Section H of the Supplementary Material that the constraints (16)-
(18) can be equivalently expressed in terms of the linear constraints (23)-(25) on vrdr′s in
the following linear program, where for each d ∈ D, we let r′d an arbitrary element in the set
Rmtp,d (say, the first element under a fixed ordering of Rmtp,d):
Sparse linear program:
min
∑
r,d,r′,s
vrdr′s
∫
L0(s; ∆)p(∆, r, d, r
′)dΛ0(∆) (20)
under the constraints:
for each ∆ ∈ G,
∑
s∈S:s∩HTRUE(∆)6=∅
∑
r,d,r′
vrdr′sp(∆, r, d, r
′) ≤ α; (21)
for each j ∈ {1, . . . , J},
∑
r,d,r′,s
vrdr′s
∫
Lj(s; ∆)p(∆, r, d, r
′)dΛj(∆) ≤ βj; (22)
for each r ∈ Rdec,
∑
d
∑
s∈S
vrdr′ds = 1; (23)
for each r ∈ Rdec, d ∈ D, r˜′ ∈ Rmtp,d,
∑
s∈S
vrdr′ds =
∑
s∈S
vrdr˜′s; (24)
for each r ∈ Rdec, d ∈ D, r′ ∈ Rmtp,d, s ∈ S : vrdr′s ≥ 0. (25)
We prove the following theorem in Section I of the Supplementary Material:
Theorem 4.1. i. (Equivalence of discretized problem and sparse linear program) The op-
timum value of the above optimization problem equals the optimum value of the discretized
problem from Section 4.1.
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ii. (Map from solution of sparse linear program to solution of discretized problem) For any
optimal solution v = {vrdr′s}r∈Rdec,d∈D,r′∈Rmtp,d,s∈S to the sparse linear program, define the
vectors x,y by the transformation:
xrd =
∑
s∈S
vrdr′s; (26)
yrdr′s =
{
vrdr′s/xrd, if xrd > 0
1/|S|, otherwise . (27)
Then x,y is a well-defined, feasible, and optimal solution to the discretized problem from
Section 4.1.
5 Application to Minimizing Expected Sample Size un-
der Power and Type I Error Constraints
We consider the adaptive design template in Figure 1b from Section 2.2 and the optimization
problem in Section 2.4. Let ESSQ denote the value of the objective function (1), which
equals the expected sample size averaged over the four mass points in Q. The sample sizes
n are a function of n as described in Section 2.2, where n is the total sample size if both
subpopulations are enrolled during stage 2. Let p1 = 1/2, α = 0.05, and let each σ
2
sa equal
a common value σ2 > 0. Let Φ denote the cumulative distribution function of the standard
normal. For comparison purposes, for β˜ = 0.05, we set
n = 4σ2{Φ−1(1− α) + Φ−1(1− β˜)}2/(∆min)2, (28)
i.e., the smallest n such that in a standard (non-adaptive) design enrolling n/2 from each
subpopulation, the uniformly most powerful test of H0C at level α = 0.05 has power 1− β˜ =
0.95 at the alternative ∆ = (∆min,∆min).
The optimal solution to the above constrained Bayes optimization problem is the same
regardless of the choice of (σ2,∆min), as we prove in Section P of the Supplementary Ma-
terial. In brief, the reason is that by (a)-(c) in Section 3, both the distribution of Z(1)
and the conditional distribution of Z(2) given (D = d,Z(1)) depend on (n, σ2,∆) only
through ∆1{n/(8σ2)}1/2 and ∆2{n/(8σ2)}1/2, i.e., the non-centrality parameters for the
subpopulations. For each j ∈ {0, 1, 2, 3}, the support of the distribution Λj is contained
15
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in Q = {(0, 0), (∆min, 0), (0,∆min), (∆min,∆min)}. Therefore, the probabilities in the ob-
jective function (1) and additional constraints (3) depend on (n, σ2,∆min) only through
∆min{n/(8σ2)}1/2, which equals the constant 2−1/2{Φ−1(1− α) + Φ−1(1− β˜)} by (28).
We applied the method from Section 4.2 to solve the above problem for each β ∈
{0.01, . . . , 0.99}. Our results show the problem is feasible whenever 1 − β ≤ 0.82, and
is infeasible otherwise. We focus on the case of 1 − β = 0.82, and denote the correspond-
ing decision rule and multiple testing procedure for the optimal solution by D∗ and M∗,
respectively. These are depicted in Figure 2.
Let Dstd denote the decision rule corresponding to a standard (non-adaptive) design that
always enrolls from both subpopulations in stage 2, i.e., Dstd = 2 for all values of the stage
1 data. Consider the above constrained Bayes optimization problem if we restrict to the
standard design, i.e., all (D,M) ∈ (E × M) that satisfy D = Dstd. Then the problem
above is infeasible for any value of 1 − β > 0.65, which we verified using the method from
Section 4.2. In contrast, the adaptive enrichment design is feasible when 1 − β ≤ 0.82,
i.e., it can achieve 82% power for all three cases (P1)-(P3), while the standard design using
the optimal multiple testing procedure inM can achieve power at most 0.64 for all three of
these cases. We similarly considered the above optimization problem restricted to a standard
design with total sample size 5n/4, i.e., the maximum total sample size that can occur in
the adaptive enrichment design; this problem is infeasible for any standard design when
1− β > 0.73. So there is still a substantial advantage for the adaptive enrichment design.
6 Comparison of Optimal Adaptive Enrichment De-
sign Versus Design Based on P-value Combination
Approach
Consider the adaptive design template in Figure 1b from Section 2.2 and the optimization
problem in Section 2.4. We apply the p-value combination approach of Bauer (1989), Bauer
and Ko¨hne (1994), Lehmacher and Wassmer (1999), with the closed testing principle of
Marcus et al. (1976); this approach has been used to construct adaptive enrichment designs
by, e.g., Bretz et al. (2006); Schmidli et al. (2006); Jennison and Turnbull (2007); Brannath
et al. (2009b); Jenkins et al. (2011b); Boessen et al. (2013b). Multiple testing procedures M
based on this approach are flexible in that they strongly control the familywise Type I error
16
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Figure 2: Optimal Decision rule D∗ and Multiple Testing Procedure M∗ for Adaptive En-
richment Design Solving Optimization Problem in Section 5
Decision Rule D∗ for Stage 2 Enrollment (z-statistics correspond to Z(1)):
Z1
Z 2
−3 −2 −1 0 1 2 3
−3
−2
−1
0
1
2
3
STOP
STOP
ALL
ONLY 1
ONLY 2
Rejection Regions of M∗ Corresponding to Each Possible Decision:
D = "ALL"
Z1
F
Z 2F
−3 −2 −1 0 1 2 3
−3
−2
−1
0
1
2
3
H02 H02,H0C
ALL
H01,
H0C
H01
D = "STOP"
Z1
F
Z 2F
−3 −2 −1 0 1 2 3
−3
−2
−1
0
1
2
3
H02 H02,
H0C
ALL
H01,
H0C
H01
D = "ONLY 1"
Z1
F
Z 2F
−3 −2 −1 0 1 2 3
−3
−2
−1
0
1
2
3
ALL
H01,
H0C
H01
D = "ONLY 2"
Z1
F
Z 2F
−3 −2 −1 0 1 2 3
−3
−2
−1
0
1
2
3
ALL
H02,
H0CH02
17
Hosted by The Berkeley Electronic Press
rate regardless of what decision rule D is used.
We applied the p-value combination approach to determine the multiple testing proce-
dure M . This approach requires specifying a combination function and local tests for each
intersection of null hypotheses. At each stage k ∈ {1, 2}, for every subset of null hypotheses
I ⊆ H, an adjusted p-value for the intersection null hypothesis HI =
⋂
H∈I H is computed
from the data in stage k, using the Dunnett intersection test (Dunnett, 1955; Jennison and
Turnbull, 2007). P-values are then combined across stages by the weighted inverse normal
rule with equal weights for each stage. Each elementary null hypothesis H ∈ H is rejected
if and only if the stage 2 combined p-value is less than 0.05 for every intersection null hy-
pothesis
⋂
H′∈I H
′ for which H ∈ I. We slightly modified this approach to incorporate early
stopping for efficacy after stage 1 as in, e.g., Jennison and Turnbull (2007), using the equiv-
alent of the boundaries of O’Brien and Fleming (1979) for the stage 1 p-values. Full details
of our implementation are given in Section Q of the Supplementary Material. The resulting
multiple testing procedure is denoted by Mpv.
The p-value combination approach does not specify a corresponding decision rule D. To
construct one, we consider a class of decision rules D that are functions of two thresholds
tc and ti, which we approximately optimize in conjunction with M
pv as described below.
Sample sizes n are as in the adaptive design template in Figure 1b from Section 2.2. Define
the decision rule D(tc,ti)(Z(1)) as follows: If the multiple testing procedure Mpv rejects any
null hypothesis at the end of stage 1, stop the trial; else, if the combined population statistic
(Z
(1)
1 +Z
(1)
2 )/
√
2 > tc, enroll both subpopulations in stage 2; else, enroll from each subpopu-
lation s for which Z
(1)
s > ti. The numerical value of D is then determined as follows: if both
subpopulations are enrolled in stage 2, then D = 2; else, if only one subpopulation s ∈ {1, 2}
is enrolled in stage 2, then D = 2 + s; else, the trial stops at the end of stage 1, i.e., D = 1.
An example of the decision rule D(tc,ti) is depicted in Figure 6.
We next define a set of adaptive enrichment designs D(tc,ti) corresponding to pairs (tc, ti)
in a grid of values; let A = {(D(tc,ti),Mpv) : (tc, ti) ∈ (−3,−2.9, . . . , 3)× (−3,−2.9, . . . , 3)}.
Each design in A strongly controls the familywise Type I error rate at level 0.05, which is a
property of the p-value combination approach. For each design in A, we computed ESSQ
and the power to reject each subset of null hypotheses. We used the results to solve the
constrained Bayes optimization problem from the previous section restricted to the set of
designs A. Specifically, for each value of 1 − β in the top row of Table 1, we computed
the smallest value of ESSQ over all designs A that satisfy (P1)-(P3) at this value of β.
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Figure 3: Decision Rule D(tc,ti) for (tc, ti) = (1.6, 0.6). (z-statistics correspond to Z
(1)). This
corresponds to the minimizer of ESSQ over A satisfying the power constraints (P1)-(P3) at
1− β = 0.74. The white area in the upper right corner corresponds to stopping the trial at
the end of stage 1.
Z1
Z 2
−3 −2 −1 0 1 2 3
−3
−2
−1
0
1
2
3
STOP
ALL
ONLY 1
ONLY 2
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Table 1: The minimum value of ESSQ, among the designs A (computed using grid search
and p-value combination approach) and among the designs E ×M (computed using sparse
linear programming approach), for various values 1− β of the power constraints (P1)-(P3).
No value is given for A when 1− β ≥ 0.78 since the problem is infeasible.
Power Constraint (1− β) 58% 62% 66% 70% 74% 78% 82%
Min. ESSQ over A 0.86n 0.89n 0.92n 0.96n 1.02n × ×
Min. ESS +Q over E ×M 0.65n 0.69n 0.73n 0.79n 0.84n 0.92n 1.03n
Also, for each such value of 1 − β, we solved the corresponding problem over the class of
designs E ×M using the sparse linear programming method from Section 4.2; the minimum
value of the objective function ESSQ is given for each class of designs in the bottom rows
of Table 1 in terms of n. At all values of 1− β we considered, the minimum value of ESSQ
was substantially lower for the optimal design among E ×M computed based on our sparse
linear programming approach, compared to the optimal design among A computed using
grid search and p-value combination approach. E.g., at 1 − β = 0.74, the value of ESSQ
for the former is 21% smaller than for the latter. In addition, the optimization problem is
infeasible for the designs in A at 1−β ≥ 0.78, i.e., it is not possible to simultaneously satisfy
the power constraints (P1)-(P3); in contrast, the problem is feasible for the class E ×M up
to power threshold 1 − β = 0.82. This shows that there are substantial gains in expected
sample size and power from using the optimal design over the class E ×M compared to the
optimal design over A. Our sparse linear programming method made it possible to compute
the optimal design over E ×M, which previously was an open problem.
7 General Form of Sparse Linear Program
We describe the general form of the sparse linear program from Section 4.2. Let v denote the
vector consisting of all variables vrdr′s for r ∈ Rdec, d ∈ D, r′ ∈ Rmtp,d, s ∈ S in lexicographic
order. Let w = |Rdec| ×
∑
d∈D |Rmtp,d| × |S|, where |B| denotes the cardinality of the set
B. Then v has w components. Define ψ =
∑
d∈D |Rmtp,d|. The general form of the sparse
linear program from Section 4.2 is
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min
v∈Rw+
cTv s.t. A(1)v ≤ a(1),A(2)v = a(2); (29)
for matrices A(1),A(2) and vectors c, a(1), a(2). The matrix A(1) has dimensions (|G|+J)×w,
and the matrix A(2) has dimensions (1+ψ)|Rdec|×w. The matrix A(1) is dense (most entries
are non-zero), while the matrix A(2) is sparse (most entries are 0) and has the form:
A(2) =
[
|Rdec| rows, each with |D| × |S| entries with 1 and the rest 0’s.
ψ|Rdec| rows, each with |S| entries = 1, |S| entries = -1, and the rest 0’s.
]
.
Though the matrix A(2) is typically much larger than A(1), the former does not dramatically
impact the computationally difficulty since it is sparse.
The vector c is dense, and the vectors a(1), a(2) have the following forms:
a(1)
T
=
(
|G| entries J entries
α, . . . , α, β1, . . . , βJ
)
, a(2)
T
=
(
|Rdec| entries ψ|Rdec| entries
1, . . . 1, 0, . . . , 0
)
.
Consider the constrained Bayes optimization problem in Section 5. The problem was
solved in two steps. First, a sparse linear program was constructed using a coarse dis-
cretization with w = 479, 570 variables, 541 Type I error constraints corresponding to
pairs of non-centrality parameters (∆1{n/(8σ2)}1/2,∆2{n/(8σ2)}1/2) in the set {(x, y) : [x ∈
{−9,−8.9, . . . , 9}, y = 0] OR [x = 0, y ∈ {−9,−8.9, . . . , 9}] OR [x ∈ {−9,−8.9, . . . , 9}, y =
−x]} (which are grids along the boundaries of the null spaces for the null hypotheses in H),
J = 3 power constraints, and 68,003 equality constraints in A(2). In step two, we used the
dual solution to this linear program to approximately identify the active constraints, and then
constructed a finer discretization with 9,208,283 variables, 27 Type I error constraints (con-
centrated in a small neighborhood of the active constraints from the solution to the first step),
J = 3 power constraints, and 1,314,989 equality constraints in A(2). The three active Type I
error constraints in the optimal solution to the second step correspond to the following pairs
of non-centrality parameters (∆1{n/(8σ2)}1/2,∆2{n/(8σ2)}1/2) : (0, 0), (0, 2.28), (2.28, 0).
This shows that the method of Hampson and Jennison (2014) would not generally work
if applied in our setting (which differs from their problem setting). This is because their ap-
proach requires that the optimal solution when only constraining Type I error at the global
null hypothesis (i.e., non-centrality parameters equal to (0, 0)) also controls familywise Type
I error at all other alternatives.
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To solve each sparse linear programming problem, we used the IBM CPLEX solver,
version 12.4. To take advantage of the extreme sparse structure of the problem, we used an
interior point algorithm. To guarantee high precision, we set the tolerance of the relative
duality gap to be 10−10. The linear program in the first step above (coarse version) took
approximately 45 minutes to solve, while the second step (finer version) took approximately
12 hours.
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